Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Open-label trial of atomo… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Open-label trial of atomoxetine hydrochloride in adults with ADHD.

Artikel i vetenskaplig tidskrift
Författare Mats Johnson
Mats Cederlund
Maria Råstam
Björn Areskoug
Christopher Gillberg
Publicerad i Journal of Attention Disorders
Volym 13
Nummer/häfte 5
Sidor 539-545
ISSN 1087-0547
Publiceringsår 2010
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 539-545
Språk en
Länkar dx.doi.org/10.1177/1087054709332372
Ämnesord Adrenergic Uptake Inhibitors, Administration & dosage, Adverse effects, Adult, Attention Deficit Disorder with Hyperactivity, Drug therapy, Drug Administration Schedule, Female, Humans, Intention to Treat Analysis, Longitudinal Studies, Male, Middle Aged, Patient Selection, Propylamines, Administration & dosage, Adverse effects, Time, Treatment Outcome
Ämneskategorier Barn- och ungdomspsykiatri

Sammanfattning

Background: While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. Methods: Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. Results: Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood pressure), decreasing efficacy or non-compliance. Conclusion: Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?